Rallybio (NASDAQ:RLYB – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($1.44) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 7:00 AM ET.
Rallybio (NASDAQ:RLYB – Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.44) by $0.96. Rallybio had a negative net margin of 911.07% and a negative return on equity of 40.53%.
Rallybio Stock Up 0.4%
Shares of NASDAQ RLYB opened at $15.99 on Thursday. The firm’s 50-day moving average price is $16.79 and its 200-day moving average price is $12.77. Rallybio has a 52-week low of $3.67 and a 52-week high of $17.57. The company has a market cap of $84.95 million, a PE ratio of -3.68 and a beta of -0.72.
Rallybio Announces Dividend
The business also recently disclosed a special dividend, which will be paid on Friday, November 13th. Investors of record on Thursday, November 5th will be given a dividend of $13.56 per share.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Rallybio from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Rallybio from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, October 6th. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat, Rallybio currently has an average rating of “Hold”.
Get Our Latest Stock Report on Rallybio
About Rallybio
Rallybio Corporation is a clinical-stage biotechnology company focused on developing medicines for patients with rare diseases, with an emphasis on conditions that affect maternal and fetal health, as well as other serious disorders with limited treatment options. The company is headquartered in New Haven, Connecticut, and its programs are intended for specialized patient populations in the United States and international markets.
Rallybio’s lead program, RLYB212, is being developed to prevent fetal and neonatal alloimmune thrombocytopenia, a rare condition in which maternal antibodies attack fetal platelets during pregnancy.
See Also
- Five stocks we like better than Rallybio
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
